Comments
Drug firm Natco Pharma on Tuesday said it has received establishment inspection report (EIR) from the US health regulator for its facility near Hyderabad.
In a BSE filing, Natco Pharma announced “successful closure of inspection” with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
The plant was inspected during the period August 5-9, 2019, it added. The USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Shares of Natco Pharma were trading 1.13 per cent higher at Rs 587.75 apiece on the BSE at 12.25 pm.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.